These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22272708)

  • 21. PIM kinase inhibitors: an updated patent review (2016-present).
    Sharma A; Dubey R; Gupta S; Asati V; Kumar V; Kumar D; Mahapatra DK; Jaiswal M; Jain SK; Bharti SK
    Expert Opin Ther Pat; 2024 May; 34(5):365-382. PubMed ID: 38842051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of low-nanomolar PIM kinase inhibitors.
    Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
    Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Pim kinases for cancer treatment: opportunities and challenges.
    Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
    Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
    Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
    Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIM kinase (and Akt) biology and signaling in tumors.
    Warfel NA; Kraft AS
    Pharmacol Ther; 2015 Jul; 151():41-9. PubMed ID: 25749412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
    Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
    Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus Entry.
    Park C; Min S; Park EM; Lim YS; Kang S; Suzuki T; Shin EC; Hwang SB
    J Virol; 2015 Oct; 89(19):10073-86. PubMed ID: 26202252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of PIM1/PIM2 kinases in tumors of the male reproductive system.
    Jiménez-García MP; Lucena-Cacace A; Robles-Frías MJ; Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Sci Rep; 2016 Nov; 6():38079. PubMed ID: 27901106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
    Liang C; Li YY
    Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.
    Mary Photini S; Chaiwangyen W; Weber M; Al-Kawlani B; Favaro RR; Jeschke U; Schleussner E; Morales-Prieto DM; Markert UR
    Exp Cell Res; 2017 Oct; 359(1):275-283. PubMed ID: 28729093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational Design of a Potent Pan-Pim Kinases Inhibitor with a Rhodanine-Benzoimidazole Structure.
    Sawaguchi Y; Yamazaki R; Nishiyama Y; Sasai T; Mae M; Abe A; Yaegashi T; Nishiyama H; Matsuzaki T
    Anticancer Res; 2017 Aug; 37(8):4051-4057. PubMed ID: 28739687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
    Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.
    Padi SKR; Singh N; Bearss JJ; Olive V; Song JH; Cardó-Vila M; Kraft AS; Okumura K
    Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20505-20510. PubMed ID: 31548394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
    Beharry Z; Zemskova M; Mahajan S; Zhang F; Ma J; Xia Z; Lilly M; Smith CD; Kraft AS
    Mol Cancer Ther; 2009 Jun; 8(6):1473-83. PubMed ID: 19509254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The PIM family of serine/threonine kinases in cancer.
    Narlik-Grassow M; Blanco-Aparicio C; Carnero A
    Med Res Rev; 2014 Jan; 34(1):136-59. PubMed ID: 23576269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.
    Białopiotrowicz E; Górniak P; Noyszewska-Kania M; Puła B; Makuch-Łasica H; Nowak G; Bluszcz A; Szydłowski M; Jabłonska E; Piechna K; Sewastianik T; Polak A; Lech-Marańda E; Budziszewska BK; Wasylecka-Juszczyńska M; Borg K; Warzocha K; Czardybon W; Gałęzowski M; Windak R; Brzózka K; Juszczyński P
    J Cell Mol Med; 2018 Jul; 22(7):3548-3559. PubMed ID: 29665227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.